Lv41
684 积分 2025-02-10 加入
Game-changing breakthroughs to redefine the landscape of the renin–angiotensin–aldosterone system in health and disease
6天前
已完结
The Renin-Angiotensin-Aldosterone System in Kidney Diseases of Cats and Dogs
6天前
已完结
The renin-angiotensin-aldosterone system and its therapeutic targets
6天前
已完结
Mechanisms of weight regain
10天前
已完结
World Health Organization Guideline on the Use and Indications of Glucagon-Like Peptide-1 Therapies for the Treatment of Obesity in Adults
10天前
已完结
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of SPH3127: A Phase I, Randomized, Double-Blind, Placebo-Controlled Trial
11天前
已完结
The Nonclinical Pharmacokinetics and Prediction of Human Pharmacokinetics of SPH3127, a Novel Direct Renin Inhibitor
11天前
已完结
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of SPH3127: A Phase I, Randomized, Double-Blind, Placebo-Controlled Trial
11天前
已完结
SPH3127 (Sitokiren), a Novel Renin Inhibitor, Suppresses Colitis Development in Mouse Models of Experimental Colitis
11天前
已完结
Orforglipron, an oral small-molecule GLP-1 receptor agonist, for the treatment of obesity in people with type 2 diabetes (ATTAIN-2): a phase 3, double-blind, randomised, multicentre, placebo-controlled trial
19天前
已完结
皖公网安备34019202002308
